Harnessing the immune response to target tumors [version 1; referees: 2 approved]

by Luisa Manning, John Nemunaitis
Published 2017-05-01

Procoagulant inhibitory properties of paclitaxel poliglumex

by John Nemunaitis, Neil Senzer, Barry Cooper, et al
Published 2010-12-01

Ovarian Cancer Immunotherapy and Personalized Medicine

by Susan Morand, Monika Devanaboyina, Hannah Staats, Laura Stanbery, John Nemunaitis
Published 2021-06-01

FDA efficiency for approval process of COVID-19 therapeutics

by Christine Cassidy, Danielle Dever, Laura Stanbery, Gerald Edelman, Lance Dworkin, John Nemunaitis
Published 2020-12-01

HER2-positive metastatic cervical cancer responsive to first and second-line treatment: A case report

by Dylan Fortman, Rochell Issa, Laura Stanbery, Mary Albrethsen, John Nemunaitis, Timothy Kasunic
Published 2020-02-01

Adenomatous polyposis coli in cancer and therapeutic implications

by Olivia Noe, Louis Filipiak, Rachel Royfman, Austin Campbell, Leslie Lin, Danae Hamouda, Laura Stanbery, John Nemunaitis
Published 2021-06-01

KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex.

by Donald D Rao, Xiuquan Luo, Zhaohui Wang, Christopher M Jay, Francis C Brunicardi, William Maltese, Luisa Manning, Neil Senzer, John Nemunaitis
Published 2018-01-01

Notch1 Activation Up-Regulates Pancreatic and Duodenal Homeobox-1

by Min Li, F. Charles Brunicardi, William E. Fisher, David Dawson, Neil Senzer, James Wu, John Nemunaitis, Shi-He Liu, Guisheng Zhou, Juehua Yu
Published 2013-07-01

Interleukin 10-Mediated Response and Correlated Anemia in a Patient with Advanced Non-Small Cell Lung Carcinoma

by Khalil Choucair, Jesse D. Kelso, Joseph R. Duff, Christine S. Cassidy, Mary T. Albrethsen, Mushtaq Ashraf, Cherian Verghese, Martin Oft, F. Charles Brunicardi, Lance Dworkin, John Nemunaitis
Published 2019-04-01

Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanomaResearch in context

by Robert H.I. Andtbacka, Thomas Amatruda, John Nemunaitis, Jonathan S. Zager, John Walker, Jason A. Chesney, Kate Liu, Cheng-Pang Hsu, Cheryl A. Pickett, Janice M. Mehnert
Published 2019-09-01

Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer

by Rodney P. Rocconi, Laura Stanbery, Luciana Madeira da Silva, Robert A. Barrington, Phylicia Aaron, Luisa Manning, Staci Horvath, Gladice Wallraven, Ernest Bognar, Adam Walter, John Nemunaitis
Published 2021-08-01

Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance

by Johnathan Oh, Minal Barve, Neil Senzer, Phylicia Aaron, Luisa Manning, Gladice Wallraven, Ernest Bognar, Laura Stanbery, Staci Horvath, Meghan Manley, John Nemunaitis, Adam Walter, Rodney P. Rocconi
Published 2020-11-01

Corrigendum to “Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance” [Gynecol. Oncol. Rep. 34 (202...

by Jonathan Oh, Minal Barve, Neil Senzer, Phylicia Aaron, Luisa Manning, Gladice Wallraven, Ernest Bognar, Laura Stanbery, Staci Horvath, Meghan Manley, John Nemunaitis, Adam Walter, Rodney P. Rocconi
Published 2021-05-01

A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms.

by Edward Wolin, Alain Mita, Amit Mahipal, Tim Meyer, Johanna Bendell, John Nemunaitis, Pam N Munster, Luis Paz-Ares, Ellen H Filvaroff, Shaoyi Li, Kristen Hege, Hans de Haan, Monica Mita
Published 2019-01-01

Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer

by Apostolia-Maria Tsimberidou, Jamie V. Shaw, Dejan Juric, Claire Verschraegen, Amy M. Weise, John Sarantopoulos, Gilberto Lopes, John Nemunaitis, Monica Mita, Haeseong Park, Barbara Ellers-Lenz, Hui Tian, Wenyuan Xiong, Remigiusz Kaleta, Razelle Kurzrock
Published 2021-08-01

PDX-1 is a therapeutic target for pancreatic cancer, insulinoma and islet neoplasia using a novel RNA interference platform.

by Shi-He Liu, Donald D Rao, John Nemunaitis, Neil Senzer, Guisheng Zhou, David Dawson, Marie-Claude Gingras, Zhaohui Wang, Richard Gibbs, Michael Norman, Nancy S Templeton, Francesco J Demayo, Bert O'Malley, Robbi Sanchez, William E Fisher, F Charles Brunicardi
Published 2012-01-01

STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial

by Matthew J. Reilley, Patricia McCoon, Carl Cook, Paul Lyne, Razelle Kurzrock, Youngsoo Kim, Richard Woessner, Anas Younes, John Nemunaitis, Nathan Fowler, Michael Curran, Qinying Liu, Tianyuan Zhou, Joanna Schmidt, Minji Jo, Samantha J. Lee, Mason Yamashita, Steven G. Hughes, Luis Fayad, Sarina Piha-Paul, Murali V. P. Nadella, Xiaokun Xiao, Jeff Hsu, Alexey Revenko, Brett P. Monia, A. Robert MacLeod, David S. Hong
Published 2018-11-01